Norstella

Norstella introduces NorstellaLinQ: https://ow.ly/nqga50TGawG. It's biopharma’s first fully integrated data asset combining RWD—open and closed claims, lab results and EMR—with Norstella’s proprietary forecasting, clinical, regulatory, payer, coverage and commercial intelligence data. Get closer to the patient than ever before. Learn more about NorstellaLinQ at the link in this post.

Norstella's Suzanne Caruso sat down with Katie Palmer of STAT to explain how we harness AI to accelerate patient access to new therapies. https://ow.ly/Cmvu50U58zQ With protocol design and investigator selection being a manual process, "Can we help the experts get to the last mile faster?" Citeline's AI-enabled SmartSolutions suite is doing precisely that. Check out the full article at the link in this post.

The 2025 Preview report has landed! https://ow.ly/4Y2H50UAwQq Featuring Evaluate forecasts of top-selling drugs, the biggest new sales generators and potential approvals for the year ahead, it's full of data-driven insight & expert commentary. Grab your copy now: https://ow.ly/4Y2H50UAwQq

Did you know that between 2019 and 2023, 31% of the world's clinical trials were conducted in China? https://ow.ly/Cwxf50Ukfc8 In this must-read article, Janelle Hart (Managing Editor), Xu Hu (Senior Reporter, APAC), and Jie (Dexter) Yan (Senior Editor, APAC) from Citeline, a Norstella company, share valuable insights into the trends fueling China's growth in clinical trials. They explore how China has emerged as a leader in drug development and discuss the challenges it faces moving forward. Click the link in this post for access to the full article. #ClinicalTrials #PharmaInnovation #ChinaBiotech #DrugDevelopment #LifeSciences

Inbox a bit quiet? Catch up on your reading with our Top 10 most-read pharma articles of 2024. https://ow.ly/7zgw50UyM2Q

Pharma companies are using lab data to reach patients faster and more effectively. https://ow.ly/jcYH50Um84w. Dr. Madeline Naylor, DHSc, MSc, ACRP-CP, Vice President of Health Informatics, RWD at Norstella, writes about how lab data is being used across the product lifecycle, from drug development to patient monitoring. Learn how NorstellaLinQ fills in the gaps associated with typical real-world data assets, enabling a 360-degree view of the patient journey. Click the link in this post to read the article. #Pipeline2Patient #FollowNorstella #Pharma #LabData #PatientJourney #ClinicalResearch

AI is revolutionizing the pharmaceutical industry, driving efficiency and innovation in drug development. https://ow.ly/EeKj50UlLe7 Our latest industry report, Assessing AI Transformation in Pharma R&D: Current & Future Impact, by Janelle Hart, Managing Editor, Custom Content at Citeline, demonstrates how AI is enhancing operational efficiency, reducing costs, and improving diagnostics. Discover the key insights and see how AI is shaping the future of drug development. Download the report at the link in this post. #Pipeline2Patient #FollowNorstella #Pharma #AI #DrugDevelopment

Have you tried the all-new Citeline News and Insights app? Access all your favorite award-winning publications, all in one place. Download the app today: https://ow.ly/yuPw50SAjV7. (Available on the App Store and Google Play.)

Want to stay ahead in the rapidly evolving biopharma landscape? Download this innovation trends white paper: https://ow.ly/WmnC50UpY0Q. As 2024 wraps up, dive into the game-changing trends in our white paper, "Innovation Trends from R&D to Market Access," by Daniel Chancellor, VP of Thought Leadership at Norstella. Discover our 2025 strategies focusing on AI in pharma R&D, tackling productivity and attrition challenges, and the critical importance of early market access. Equip yourself with these essential insights and lead the charge into the new year. Download your free copy now. #Pipeline2Patient #FollowNorstella

In 2025, we can expect significant progress in medicine, with many new therapies set to be approved. https://ow.ly/pb5250TKMNG These treatments will cover various medical conditions and include new drugs and expanded treatments. This article details these developments and potential new therapies, from apitegromab to Zegalogue. Read the article at the link in this post to see what to expect next year.